These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 32258540)

  • 1.
    Silva R; Gullo I; Carneiro F
    Porto Biomed J; 2016; 1(1):4-11. PubMed ID: 32258540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between Helicobacter pylori and expression of programmed death-1 and its ligand in gastric intraepithelial neoplasia and early-stage gastric cancer.
    Shen B; Qian A; Lao W; Li W; Chen X; Zhang B; Wang H; Yuan F; Sun Y
    Cancer Manag Res; 2019; 11():3909-3919. PubMed ID: 31190978
    [No Abstract]   [Full Text] [Related]  

  • 3. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the PD-1 pathway: a new hope for gastrointestinal cancers.
    Bilgin B; Sendur MA; Bülent Akıncı M; Şener Dede D; Yalçın B
    Curr Med Res Opin; 2017 Apr; 33(4):749-759. PubMed ID: 28055269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.
    Taieb J; Moehler M; Boku N; Ajani JA; Yañez Ruiz E; Ryu MH; Guenther S; Chand V; Bang YJ
    Cancer Treat Rev; 2018 May; 66():104-113. PubMed ID: 29730461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased Programmed Death-Ligand 1 is an Early Epithelial Cell Response to Helicobacter pylori Infection.
    Holokai L; Chakrabarti J; Broda T; Chang J; Hawkins JA; Sundaram N; Wroblewski LE; Peek RM; Wang J; Helmrath M; Wells JM; Zavros Y
    PLoS Pathog; 2019 Jan; 15(1):e1007468. PubMed ID: 30703170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.
    Carbognin L; Pilotto S; Milella M; Vaccaro V; Brunelli M; Caliò A; Cuppone F; Sperduti I; Giannarelli D; Chilosi M; Bronte V; Scarpa A; Bria E; Tortora G
    PLoS One; 2015; 10(6):e0130142. PubMed ID: 26086854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.
    Gong J; Chehrazi-Raffle A; Reddi S; Salgia R
    J Immunother Cancer; 2018 Jan; 6(1):8. PubMed ID: 29357948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer: an evidence-based review of place in therapy.
    Mehta R; Shah A; Almhanna K
    Onco Targets Ther; 2018; 11():6525-6537. PubMed ID: 30323626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for Esophageal and Gastric Cancer.
    Kelly RJ
    Am Soc Clin Oncol Educ Book; 2017; 37():292-300. PubMed ID: 28561677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
    Nishijima TF; Shachar SS; Nyrop KA; Muss HB
    Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
    Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
    Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma.
    Lantuejoul S; Damotte D; Hofman V; Adam J
    J Thorac Dis; 2019 Jan; 11(Suppl 1):S89-S101. PubMed ID: 30775032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer.
    Kok VC
    Front Oncol; 2020; 10():268. PubMed ID: 32185135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.
    Fashoyin-Aje L; Donoghue M; Chen H; He K; Veeraraghavan J; Goldberg KB; Keegan P; McKee AE; Pazdur R
    Oncologist; 2019 Jan; 24(1):103-109. PubMed ID: 30120163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.
    Bellmunt J; Powles T; Vogelzang NJ
    Cancer Treat Rev; 2017 Mar; 54():58-67. PubMed ID: 28214651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
    Brody R; Zhang Y; Ballas M; Siddiqui MK; Gupta P; Barker C; Midha A; Walker J
    Lung Cancer; 2017 Oct; 112():200-215. PubMed ID: 29191596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitors for nonsmall cell lung cancer treatment.
    Chen YM
    J Chin Med Assoc; 2017 Jan; 80(1):7-14. PubMed ID: 27693088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.